MAD2L1BP

Across TCGA pan-cancer cohorts, MAD2L1BP mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MAD2L1BP’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MAD2L1BP mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MAD2L1BP is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where MAD2L1BP tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAD2L1BP mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.308	<.001	7	view →
COAD	All	All	+0.256	.002	6	view →
HNSC	Male	All	−0.306	.032	3	view →
OV	All	All	+0.395	.043	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MAD2L1BP–CCRCC

Open the CCRCC breakdown →